In- and out-licensing evaluation

We help you to identify, qualify, and prioritize possible in- and out-licensing evaluation candidates and evaluate their commercial potential. With substantial capabilities including rapid assessment and comprehensive due diligence, we can provide information and guidance across each phase of your engagement.

In- and out-licensing evaluation

A diverse team with a proven track record

Our clinical, epidemiology, access, and forecasting experts work collaboratively to support holistic and comprehensive in- and out-licensing evaluations, ensuring confident decision-making.

We can support you as part of a long-term strategic process or as tactical support at critical points that may require an independent validation.

Drawing on trusted data sources

We draw upon data sources such as the Oracle Life Sciences Epi Database, Oracle Life Sciences CancerMPact, and Oracle EHR Real-World Data, plus vital medical literature, government databases, and patient surveys. Our experts can deliver accurate, holistic insights into market trends to inform your decisions regarding in- and out-licensing opportunities.

Licensing evaluation for diverse commercial applications

Our experts work across disciplines to support your decision-making around licensing options, enabling you to

  • Assess the overall landscape, competitive market, and market access
  • Quantify the clinical and commercial value of your products
  • Identify and validate partnership or acquisition opportunities
  • Conduct commercial and scientific due diligence
  • Forecast revenue, analyze cash flow, and value assets
  • Map opportunities to organizational strategy and goals

Get started with Oracle Life Sciences


Get in touch

Talk to a team member about Oracle solutions for life sciences.


Follow our podcast

Hear from scientists, clinicians, and industry leaders from pharma, biotech and CROs, who are driving innovation in life sciences and health.


Get technical support

Explore technical support contacts and resources.